MERCK DOWNPLAYS TAGAMET EXPERIENCE FOR PEPCID AC OTC SWITCH REVIEW
This article was originally published in The Tan Sheet
Executive Summary
MERCK DOWNPLAYS TAGAMET EXPERIENCE FOR PEPCID AC OTC SWITCH REVIEW during an April 12 meeting with securities analysts at Merck's research facilities in Rahway, N.J. Merck Research Labs President Edward Scolnick, MD, maintained that Merck has "much better data" on its H[2] antagonist Pepcid (famotidine) for the treatment of heartburn than SmithKline Beecham had for Tagamet (cimetidine). "It is a completely different world of clinical research that our group has generated," Scolnick told the analysts.